- Generative AI in healthcare, which refers to AI systems that can generate medical content, support clinical decision-making, and accelerate drug discovery, is becoming a transformative force across diagnostics, treatment planning, and personalized medicine
- The growing demand for generative AI solutions is driven by rising healthcare data volumes, increasing adoption of digital health technologies, and the need to improve clinical efficiency and patient outcomes
- North America dominated the generative AI in healthcare market with the largest revenue share of 40.8% in 2024, attributed to early AI adoption, strong R&D infrastructure, significant investments from both public and private sectors, and the presence of leading tech companies and healthcare institutions. The U.S. in particular has seen rapid deployment of generative AI in clinical workflows, radiology, and genomics
- Asia-Pacific is expected to be the fastest-growing region in the generative AI in healthcare market during the forecast period, owing to growing healthcare digitization, supportive government policies, expanding medical tourism, and increasing investment in AI research, particularly in countries like China, India, and Japan
- The Drug Discovery and Development segment dominated the generative AI in healthcare market with the largest revenue share of 43.2% in 2024, driven by the ability of generative AI to streamline early-stage research, generate novel compounds, and reduce drug development timelines and costs. The segment benefits from growing investments in pharmaceutical R&D and AI-driven molecular modeling platforms
